<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Research Foundation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fphar.2012.00136</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The Role of Bile Pigments in Health and Disease: Effects on Cell Signaling, Cytotoxicity, and Cytoprotection</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kapitulnik</surname> <given-names>Jaime</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn001">&#x0002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Maines</surname> <given-names>Mahin D.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Laboratory of Drug Metabolism, Institute of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem</institution> <country>Jerusalem, Israel</country></aff>
<aff id="aff2"><sup>2</sup><institution>Biochemistry and Biophysics, University of Rochester School of Medicine</institution> <country>Rochester, NY, USA</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Th&#x000E9;ophile Godfraind, Universit&#x000E9; Catholique de Louvain, Belgium</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Th&#x000E9;ophile Godfraind, Universit&#x000E9; Catholique de Louvain, Belgium</p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x0002A;Correspondence: <email>jaimek&#x00040;savion.huji.ac.il</email></p></fn>
<fn fn-type="other" id="fn002"><p>This article was submitted to Frontiers in Drug Metabolism and Transport, a specialty of Frontiers in Pharmacology.</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>07</month>
<year>2012</year>
</pub-date>
<pub-date pub-type="collection">
<year>2012</year>
</pub-date>
<volume>3</volume>
<elocation-id>136</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>06</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>06</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2012 Kapitulnik and Maines.</copyright-statement>
<copyright-year>2012</copyright-year>
<license license-type="open-access" xlink:href="http://www.frontiersin.org/licenseagreement"><p>This is an open-access article distributed under the terms of the <uri xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</uri>, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.</p></license>
</permissions>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="19"/>
<page-count count="2"/>
<word-count count="1382"/>
</counts>
</article-meta>
</front>
<body>
<p>Degradation of heme involves its conversion to biliverdin by heme oxygenase followed by reduction of biliverdin to bilirubin by biliverdin reductase. There is ample evidence for the role of heme oxygenase in protecting cells from the toxic effects of heme, as well as for the pleiotropic functions of biliverdin reductase in cell signaling and regulation of gene expression. This enzyme plays a major role in glucose uptake and the stress response. Bilirubin has been shown to behave as a &#x0201C;double-edged sword.&#x0201D; It can exert either cytotoxic or cytoprotective effects, depending on the blood and/or tissue concentration of its free fraction, the nature of the target cell or tissue, and the cellular redox state. The central nervous system is particularly sensitive to the neurotoxic effects of bilirubin. Its antioxidant effect is the basis for the proposed cardioprotective effect of bilirubin in humans with moderate hyperbilirubinemia, as is the case in subjects with the Gilbert syndrome.</p>
<p>This Research Topic forum is intended to serve as a platform for updating information and presenting advances in basic and clinical research in the above and related subjects. The topic is discussed by leading experts in the field of bile pigments, and presented in 15 Reviews, 3 Original Research articles and 1 Opinion article. It covers important aspects related to the enzymes involved in the heme catabolic pathway: the role of heme oxygenase in inflammation and fibrosis (Lundvig et al., <xref ref-type="bibr" rid="B11">2012</xref>) as well as in atherosclerosis (Araujo et al., <xref ref-type="bibr" rid="B1">2012</xref>) and immune-mediated inflammatory diseases (Larsen et al., <xref ref-type="bibr" rid="B10">2012</xref>), the regulation of cell signaling by biliverdin reductase and its peptide fragments (Gibbs et al., <xref ref-type="bibr" rid="B6">2012</xref>), and the regulation of bilirubin clearance (Bock, <xref ref-type="bibr" rid="B2">2011</xref>).</p>
<p>The role of glial cells and inflammation in bilirubin neurotoxicity (Brites, <xref ref-type="bibr" rid="B3">2012</xref>) and the transport and metabolism of bilirubin at blood-brain interfaces and neural cells (Gazzin et al., <xref ref-type="bibr" rid="B5">2012</xref>) illustrate the complex nature of bilirubin-induced brain damage. The effects of bilirubin vary with age (Dennery, <xref ref-type="bibr" rid="B4">2012</xref>), and metalloporphyrins have been suggested to reduce excessive hyperbilirubinemia and brain damage in newborns (Schulz et al., <xref ref-type="bibr" rid="B16">2012</xref>).</p>
<p>The regulatory properties of bile pigments and the role of biliverdin reductase in mediating their antioxidative (Jansen and Daiber, <xref ref-type="bibr" rid="B7">2012</xref>) and anti-inflammatory effects (Wegiel and Otterbein, <xref ref-type="bibr" rid="B19">2012</xref>), and their role in aging and age-related diseases (Kim and Park, <xref ref-type="bibr" rid="B9">2012</xref>), are only part of the known protective functions of bile pigments. Bilirubin displays antiviral activity (Santangelo et al., <xref ref-type="bibr" rid="B14">2012</xref>; Schmidt et al., <xref ref-type="bibr" rid="B15">2012</xref>), ameliorates renal hemodynamics and blood pressure in an animal model of hypertension (Stec et al., <xref ref-type="bibr" rid="B17">2012</xref>), and has beneficial effects in pulmonary and vascular diseases (Ryter, <xref ref-type="bibr" rid="B13">2012</xref>). The protective effects of bilirubin in the vasculature include inhibition of neointima formation and reduction of vascular smooth muscle cell proliferation and migration (Peyton et al., <xref ref-type="bibr" rid="B12">2012</xref>). In microvascular endothelial cells, low (&#x0201C;physiological&#x0201D;) bilirubin concentrations induce apoptosis, which is exacerbated under hyperglycemic conditions. Endothelial cells of the blood-brain barrier are particularly sensitive to these effects of bilirubin (Kapitulnik et al., <xref ref-type="bibr" rid="B8">2012</xref>).</p>
<sec>
<title>Conclusion</title>
<p>Bilirubin, which has been considered for decades to be a toxic waste product of heme catabolism, is now recognized as an endogenous cytoprotective compound at low (&#x0201C;physiological&#x0201D;) concentrations. However, its protective effects have been demonstrated <italic>in vitro</italic>, mainly in peripheral tissues, while its neurotoxicity remains unchallenged.</p>
<p>Although moderately elevated plasma bilirubin levels (as those of subjects with Gilbert syndrome) have been shown in retrospective and prospective clinical studies to be associated with a decreased risk of cardiovascular diseases (Vitek, <xref ref-type="bibr" rid="B18">2012</xref>), there is still no general concensus in applying this knowledge in manipulating bilirubin levels for the prevention of cardiovascular and associated diseases. Stimulation of biliverdin reduction and/or inhibition of bilirubin conjugation are highly questionable with regards to their safety in humans, particularly in the scenario of a life-long treatment. We hope that the work presented in this Research Topic will stimulate further basic and clinical research in the area of bile pigments and its pathological as well as therapeutic implications.</p>
</sec>
</body>
<back>
<ack>
<p>The Topic Editors express their gratitude to the contributors of articles for submitting their work to Frontiers in Pharmacology and for their collaboration in the review process, to the many Review Editors and external Reviewers who contributed valuable comments in the Interactive Review forum, and to the Editorial and Production teams of Frontiers for their expert work and assistance in the publication process.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Araujo</surname> <given-names>J. A.</given-names></name> <name><surname>Zhang</surname> <given-names>M.</given-names></name> <name><surname>Yin</surname> <given-names>F.</given-names></name></person-group> (<year>2012</year>). <article-title>Heme oxygenase-1, oxidation, inflammation and atherosclerosis</article-title>. <source>Front. Pharmacol.</source> <volume>3</volume>:<fpage>119</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00119</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bock</surname> <given-names>K.W.</given-names></name></person-group> (<year>2011</year>). <article-title>Regulation of bilirubin clearance by ligand-activated transcription factors of the endo- and xenobiotic metabolism system</article-title>. <source>Front. Pharmacol</source>. <volume>2</volume>:<fpage>82</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2011.00082</pub-id><pub-id pub-id-type="pmid">22207850</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brites</surname> <given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>The evolving landscape of neurotoxicity by unconjugated bilirubin: role of glial cells and inflammation</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>88</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00088</pub-id><pub-id pub-id-type="pmid">22661946</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dennery</surname> <given-names>P. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Evaluating the beneficial and detrimental effects of bile pigments in early and later life</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>115</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00115</pub-id><pub-id pub-id-type="pmid">22737125</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gazzin</surname> <given-names>S.</given-names></name> <name><surname>Strazielle</surname> <given-names>N.</given-names></name> <name><surname>Tiribelli</surname> <given-names>C.</given-names></name> <name><surname>Ghersi-Egea</surname> <given-names>J. F.</given-names></name></person-group> (<year>2012</year>). <article-title>Transport and metabolism at blood-brain interfaces and in neural cells: relevance to bilirubin-induced encephalopathy</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>89</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00089</pub-id><pub-id pub-id-type="pmid">22629246</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibbs</surname> <given-names>P. E.</given-names></name> <name><surname>Tudor</surname> <given-names>C.</given-names></name> <name><surname>Maines</surname> <given-names>M. D.</given-names></name></person-group> (<year>2012</year>). <article-title>Biliverdin reductase: more than a namesake - the reductase, its Peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>31</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00031</pub-id><pub-id pub-id-type="pmid">22419908</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname> <given-names>T.</given-names></name> <name><surname>Daiber</surname> <given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Direct antioxidant properties of bilirubin and biliverdin. Is there a role for biliverdin reductase?</article-title> <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>30</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00030</pub-id><pub-id pub-id-type="pmid">22438843</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kapitulnik</surname> <given-names>J.</given-names></name> <name><surname>Benaim</surname> <given-names>C.</given-names></name> <name><surname>Sasson</surname> <given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Endothelial cells derived from the blood-brain barrier and islets of Langerhans differ in their response to the effects of bilirubin on oxidative stress under hyperglycemic conditions</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>131</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00131</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>S. Y.</given-names></name> <name><surname>Park</surname> <given-names>S. C.</given-names></name></person-group> (<year>2012</year>). <article-title>Physiological antioxidative network of the bilirubin system in aging and age-related diseases</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>45</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00045</pub-id><pub-id pub-id-type="pmid">22457648</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname> <given-names>R.</given-names></name> <name><surname>Gouveia</surname> <given-names>Z.</given-names></name> <name><surname>Soares</surname> <given-names>M. P.</given-names></name> <name><surname>Gozzelino</surname> <given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Heme cytotoxicity and the pathogenesis of immune-mediated inflammatory diseases</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>77</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00077</pub-id><pub-id pub-id-type="pmid">22586395</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lundvig</surname> <given-names>D. M.</given-names></name> <name><surname>Immenschuh</surname> <given-names>S.</given-names></name> <name><surname>Wagener</surname> <given-names>F. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Heme oxygenase, inflammation, and fibrosis: the good, the bad, and the ugly?</article-title> <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>81</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00081</pub-id><pub-id pub-id-type="pmid">22586396</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peyton</surname> <given-names>K. J.</given-names></name> <name><surname>Shebib</surname> <given-names>A. R.</given-names></name> <name><surname>Azam</surname> <given-names>M. A.</given-names></name> <name><surname>Liu</surname> <given-names>X. M.</given-names></name> <name><surname>Tulis</surname> <given-names>D. A.</given-names></name> <name><surname>Durante</surname> <given-names>W.</given-names></name></person-group> (<year>2012</year>). <article-title>Bilirubin inhibits neointima formation and vascular smooth muscle cell proliferation and migration</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>48</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00048</pub-id><pub-id pub-id-type="pmid">22470341</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ryter</surname> <given-names>S. W.</given-names></name></person-group> (<year>2012</year>). <article-title>Bile pigments in pulmonary and vascular disease</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>39</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00039</pub-id><pub-id pub-id-type="pmid">22408625</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santangelo</surname> <given-names>R.</given-names></name> <name><surname>Mancuso</surname> <given-names>C.</given-names></name> <name><surname>Marchetti</surname> <given-names>S.</given-names></name> <name><surname>Di Stasio</surname> <given-names>E.</given-names></name> <name><surname>Pani</surname> <given-names>G.</given-names></name> <name><surname>Fadda</surname> <given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Bilirubin: an endogenous molecule with antiviral activity in vitro</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>36</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00036</pub-id><pub-id pub-id-type="pmid">22408623</pub-id></citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname> <given-names>W. N.</given-names></name> <name><surname>Mathahs</surname> <given-names>M. M.</given-names></name> <name><surname>Zhu</surname> <given-names>Z.</given-names></name></person-group> (<year>2012</year>). <article-title>Heme and HO-1 inhibition of HCV, HBV, and HIV</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>129</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00129</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname> <given-names>S.</given-names></name> <name><surname>Wong</surname> <given-names>R.J.</given-names></name> <name><surname>Vreman</surname> <given-names>H.J.</given-names></name> <name><surname>Stevenson</surname> <given-names>D.K.</given-names></name></person-group> (<year>2012</year>). <article-title>Metalloporphyrins - an update</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>68</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00068</pub-id><pub-id pub-id-type="pmid">22557967</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stec</surname> <given-names>D. E.</given-names></name> <name><surname>Hosick</surname> <given-names>P. A.</given-names></name> <name><surname>Granger</surname> <given-names>J. P.</given-names></name></person-group> (<year>2012</year>). <article-title>Bilirubin, renal hemodynamics, and blood pressure</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>18</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00018</pub-id><pub-id pub-id-type="pmid">22347861</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vitek</surname> <given-names>L.</given-names></name></person-group> (<year>2012</year>). <article-title>The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>55</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00055</pub-id><pub-id pub-id-type="pmid">22493581</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wegiel</surname> <given-names>B.</given-names></name> <name><surname>Otterbein</surname> <given-names>L. E.</given-names></name></person-group> (<year>2012</year>). <article-title>Go green: the anti-inflammatory effects of biliverdin reductase</article-title>. <source>Front. Pharmacol</source>. <volume>3</volume>:<fpage>47</fpage>.<pub-id pub-id-type="doi">10.3389/fphar.2012.00047</pub-id><pub-id pub-id-type="pmid">22438844</pub-id></citation></ref>
</ref-list>
</back>
</article>
